Oxaliplatin is an FDA-approved platinum-based antineoplastic medication.

In the pediatric population, oxaliplatin is used for treating refractory or relapsed solid tumors in combination with etoposide or ifosfamide or gemcitabine or irinotecan or fluorouracil, and leucovorin.

The following are the off-label indications for oxaliplatin:

- Advanced biliary adenocarcinoma in combination with capecitabine (a regimen known as CAPOX) or gemcitabine.

- Fludarabine refractory chronic lymphocytic leukemia in combination with fludarabine, cytarabine, and rituximab.

- Esophageal and gastric cancers in combination with epirubicin or capecitabine or docetaxel, leucovorin, and fluorouracil.

- Refractory neuroendocrine tumors in combination with capecitabine.

- Refractory or relapsed non-Hodgkin lymphoma in combination with gemcitabine and rituximab.

- Advanced ovarian cancer.

- Advanced pancreatic cancer in combination with capecitabine or fluorouracil, leucovorin, and irinotecan.

- Refractory testicular cancer in combination with gemcitabine and paclitaxel.